CPT code 20200 represents a surgical muscle biopsy to obtain superficial muscle tissue for diagnostic evaluation. The code is used when clinicians suspect neuromuscular disease, inflammatory myopathy, infection, or metabolic conditions that require histologic or microbiologic examination. Nationally, muscle biopsy remains an important diagnostic tool in neurology and pathology pathways because tissue analysis can change diagnosis and influence treatment plans.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The coverage landscape and payment practices for surgical biopsies like this one affect access to definitive diagnosis across outpatient and hospital settings.

Readers will find clinical context for the procedure, typical settings where it is performed, and the elements that influence billing and coding for a superficial muscle biopsy. The publication summarizes benchmarks and common payer practices where available, highlights policy and coding considerations that impact claim processing, and outlines what documentation commonly supports medical necessity. Data not available in the input is noted where applicable.